Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CRDL | US
-0.02
-1.96%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
05/03/2026
1.00
1.00
1.03
1.00
Cardiol Therapeutics Inc. a clinical-stage life sciences company focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx which is in Phase II/III multi-national randomized double-blind and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19 as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville Canada.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Negative Momentum (Declining Price)
Price Below SMA10D
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
39.2%1 month
49.7%3 months
51.3%6 months
53.7%-
-
13.69
0.01
0.01
0.30
178.81
-
-31.66M
79.61M
79.61M
-
-
-
-
-108.44
1.79
1.06
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.09
Range1M
0.15
Range3M
0.20
Rel. volume
0.52
Price X volume
179.25K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Universe Pharmaceuticals INC | UPC | Drug Manufacturers-Specialty & Generic | 2.7 | 63.84M | 2.27% | n/a | 24.34% |
| Cannex Capital Holdings Inc | ARRXF | Drug Manufacturers-Specialty & Generic | 0.24 | 61.16M | -4.00% | n/a | 0.50% |
| Cumberland Pharmaceuticals Inc | CPIX | Drug Manufacturers-Specialty & Generic | 3.52 | 49.62M | -4.09% | n/a | 81.86% |
| Lipocine Inc | LPCN | Drug Manufacturers-Specialty & Generic | 8.19 | 43.80M | -2.85% | n/a | 0.00% |
| INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 0.8504 | 38.92M | 0.05% | n/a | 28.90% |
| SCYNEXIS Inc | SCYX | Drug Manufacturers-Specialty & Generic | 0.7925 | 30.00M | 2.26% | n/a | 25.73% |
| Provectus Biopharmaceuticals Inc | PVCT | Drug Manufacturers-Specialty & Generic | 0.0523 | 21.96M | 0.58% | n/a | 0.00% |
| India Globalization Capital Inc | IGC | Drug Manufacturers-Specialty & Generic | 0.29 | 21.93M | 0.07% | n/a | 4.33% |
| China SXT Pharmaceuticals Inc | SXTC | Drug Manufacturers-Specialty & Generic | 2.04 | 7.09M | 2.00% | n/a | 19.00% |
| PRFX | PRFX | Drug Manufacturers-Specialty & Generic | 2.75 | 6.12M | -1.43% | n/a | -2.89% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Unifi Inc | UFI | Textile Manufacturing | 3.89 | 71.01M | -1.77% | n/a | 52.56% |
| ILAG | ILAG | Building Products & Equipment | 2.32 | 41.90M | 0.87% | n/a | 5.48% |
| Culp Inc | CULP | Textile Manufacturing | 3.24 | 40.47M | -1.82% | n/a | 11.29% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.29 | 33.46M | -2.04% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.71 | 13.72M | 23.48% | n/a | 58.43% |
| The Dixie Group Inc | DXYN | Textile Manufacturing | 0.446 | 6.86M | 0.00% | n/a | 422.08% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.404 | 3.85M | -1.46% | n/a | 19.98% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.49 | 3.81M | -4.95% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.47 | 1.36M | 0.00% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0071 | 654.72K | 0.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.30 | 24.85 | Cheaper |
| Ent. to Revenue | 178.81 | 361.91 | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 13.69 | 13.15 | Par |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 51.31 | 65.24 | Lower Risk |
| Debt to Equity | 0.01 | -1.88 | Expensive |
| Debt to Assets | 0.01 | 0.48 | Cheaper |
| Market Cap | 79.61M | 3.71B | Emerging |